ReviewFrontiers in endocrinology2023
Predictive markers for anti-inflammatory treatment response in thyroid eye disease.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Upregulation of S100A9 in orbital tissues of patients with thyroid eye disease.International ophthalmology · 2026Article
- Development and validation of a nomogram for predicting non-response to tocilizumab in thyroid eye disease: a retrospective study.BMC ophthalmology · 2026Article
- A Deep Learning Framework for Predicting Teprotumumab Treatment Response in Thyroid Eye Disease.Ophthalmology science · 2026Article
- Sarilumab in the management of Graves orbitopathy with low clinical activity scores.Scientific reports · 2026Article
- Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves' disease.Endocrine journal · 2025Article
- Multidimensional predictive model for assessing clinical activity in thyroid eye disease.Frontiers in medicine · 2025Article
- Combining biomarkers to predict the disease activity of graves' ophthalmopathy: a combinatory model of the NLR, TRAb and FT4.Frontiers in endocrinology · 2025Article
- Whole-orbit-based multiparametric assessment of disease activity of thyroid eye disease on Dixon MRI.International ophthalmology · 2024Article
- The circulating IL-35Immunity, inflammation and disease · 2024Article
- Advances in artificial intelligence in thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-inflammatory treatment is the primary and vital therapeutic approach for active, moderate-to-severe thyroid eye disease (TED). Accurate pretreatment prediction of treatment response is of paramount importance for the prognosis of patients. However, relying solely on the clinical activity score asa determinant of activity has led to unsatisfactory treatment outcomes. In recent years, significant advancements have been made in identifying predictive markers for anti-inflammatory treatment response in TED, clinical markers, body fluid biomarkers and imaging biomarkers. Several clinical studies have developed prediction models based on these markers. However, there is still a lack of comprehensive elucidation or comparison between the different markers. Therefore, this review aims to provide a detailed analysis of the definition, characteristics, and application of predictive markers for anti-inflammatory treatment response in TED. Through detailed literature search, 26 articles applying anti-inflammatory treatment effect prediction with a total of 1948 TED patients were used for analysis and discussion. By gaining a better understanding of the current research on predictive markers, we can accelerate and guide the exploration of treatment prediction strategies, leading us towards an era of precise therapy for TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.